To test whether these pathways were also critical for CD138 expression on lupus T cells, we treated CD4+TCRβ+CD138- cells with rapamycin, a specific mTOR inhibitor, and assessed the increase in CD138 expression. The gene discussed is MTOR; the disease is systemic lupus erythematosus.